- Home
- PCRX vs MAX Comparison
PCRX vs MAX Comparison
Compare PCRX & MAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- MAX
- Stock Information
- Founded
- PCRX 2006
- MAX 2014
- Country
- PCRX United States
- MAX United States
- Employees
- PCRX N/A
- MAX N/A
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- MAX Industrial Machinery/Components
- Sector
- PCRX Health Care
- MAX Industrials
- Exchange
- PCRX Nasdaq
- MAX Nasdaq
- Market Cap
- PCRX 604.7M
- MAX 613.7M
- IPO Year
- PCRX 2011
- MAX 2020
- Fundamental
- Price
- PCRX $22.36
- MAX $11.14
- Analyst Decision
- PCRX Buy
- MAX Buy
- Analyst Count
- PCRX 10
- MAX 8
- Target Price
- PCRX $27.60
- MAX $22.00
- AVG Volume (30 Days)
- PCRX 810.1K
- MAX 460.9K
- Earning Date
- PCRX 02-27-2025
- MAX 02-18-2025
- Dividend Yield
- PCRX N/A
- MAX N/A
- EPS Growth
- PCRX N/A
- MAX N/A
- EPS
- PCRX N/A
- MAX 0.19
- Revenue
- PCRX $694,957,000.00
- MAX $681,230,000.00
- Revenue This Year
- PCRX $4.83
- MAX $124.41
- Revenue Next Year
- PCRX $2.16
- MAX $31.11
- P/E Ratio
- PCRX N/A
- MAX $59.01
- Revenue Growth
- PCRX 4.40
- MAX 72.47
- 52 Week Low
- PCRX $11.16
- MAX $10.21
- 52 Week High
- PCRX $34.01
- MAX $25.78
- Technical
- Relative Strength Index (RSI)
- PCRX 70.92
- MAX 45.21
- Support Level
- PCRX $18.18
- MAX $10.28
- Resistance Level
- PCRX $22.36
- MAX $11.51
- Average True Range (ATR)
- PCRX 1.13
- MAX 0.47
- MACD
- PCRX 0.30
- MAX 0.08
- Stochastic Oscillator
- PCRX 93.11
- MAX 53.26
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.
About MAX MediaAlpha Inc.
MediaAlpha Inc provides a platform that facilitates insurance carriers and distributors target and acquire customers. The company's technology platform brings insurance carriers and consumers together through a real-time, transparent, and results-driven ecosystem. It acts as a customer acquisition channel in the areas of property & casualty insurance, health insurance, and life insurance. It operates in the United States and generates revenue by earning a fee for each consumer referral sold on its platform.